Drug Pipeline
GMP will produce and sell the formulas within the Drug Pipeline under the Canadian Cannabis Act. This being said, for purposes of DRUG establishment, the following cannabinoid-based formulas and their uses are currently investigational and have not yet been approved by Health Canada or the F.D.A. for their intended uses.
PRE-CLINICAL COMPLETED
Synthesis & stabilization of nano-formulations
13 standard indications with delivery systems
Saline and IV solutions
Proprietary topical solutions
Nebulizer solution
Gel cap; hard tabs: XR, IR; transdermal delivery development
Observational retrospective reviews of ~2000 patients
PHASE 2
Orphan disease formulation synthesis & stabilization (Q1 2022)
Pre-clinical toxicology pharmacodynamics, pharmacokinetics of formulations 2022 – 2023
Cardiac Amyloidosis FDA Designation (2022) Observational (2022) Clinical (2023-) Regulatory submission (2026)
Pain, Sleep, Mood NHLAA Clinical (2022-2024) Regulatory submission (2026)
Cerebral Palsy FDA Designation (2022) Observational (2022)Clinical (2023) Regulatory submission (2026)
PHASE 3
Autism Clinical Trial (Israel)
Cannabinoids are clearly safer than opiates
(it is impossible to overdose on and far less
addictive) and it can take the place
of NSAID”Peter Grinspoon, MD
Harvard Health Publishing, 2020
